Clozapine s side-effects put into perspective.

Size: px
Start display at page:

Download "Clozapine s side-effects put into perspective."

Transcription

1 Clozapine s side-effects put into perspective. Dan Cohen, psychiatrist FACT-team Heerhugowaard, The Netherlands Mental Health Organization North-Holland North, Netherlands, Europe

2 Disclosure No conflict of interests Membership of the Dutch Clozapine Collaboration Group

3 The Low- or Netherlands ( Holland ) with 17 million inhabitants FACT NHN 3

4 The special effects of clozapine: when is it time for the drug of last resort? Grant your patient an adequate trial

5 Side-effects a) Uncommon dangerous side-effects: - definition - incidence - detection - treatment b) Common & harmless, potentially dangerous side-effects: - incidence - detection - treatment

6 a. Uncommon dangerous side-effects Side-effects that are - uncommon - emerge during clozapine treatment - lethal when not timely diagnosed and adequately treated

7 How lethal are these side effects? Review of literature between Agranulocytosis - DKA - Myocarditis/cardiomyopathy Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012

8 Leukopenia and agranulocytosis 1. The first thing that comes to mind. 2. Clozapine s best studied serious side-effect. 3. This side-effect has negatively affected clozapine prescription

9 Leukopenia and agranulocytosis: the cut-off points US UK Australia Moderate leukopenia WBC 3000 WBC 3000 or ANC < 2000 WBC 3000 Severe leukopenia WBC < 2000 WBC <2000 or ANC <1000 WBC < 2000 Agranulocytosis WBC 1000 or WBC: white blood cell count ANC: absolute neutrophil count ANC 500 WBC 1000 or ANC <500 WBC 1000 or ANC 500 V. Kumar. FDA.gov

10 Differential diagnosis of leukopenia 1. Benign ethnic neutropenia (BEN) 2. Intercurrent bacterial or viral infection 3. Diurnal variation: leucocytes counts in blood shows a diurnal variation: lowest in the morning, highest in the afternoon

11 Benign Ethnic Neutropenia Definition Lower mean white blood cell (WBC) count without any signs of illness = lower WBC count in the normal, healthy population. Population People of African, Caribbean or Middle-Eastern origin

12 BEN: cut-off points WBC Neutrophils BEN Regular BEN Regular Green (=satisfactory WBC) > 3,0 x 10 9 > 3,5 x 10 9 > 1,5 x 10 9 > 2,0 x 10 9 Amber (repeat WBC) 2,5 3,0 x ,0-3,5 x ,0-1,5 x ,5-2,0 x 10 9 Red (= immediate cessation of clozapine) < 2,5 x 10 9 < 3,0 x 10 9 < 1,0 x 10 9 < 1,5 x 10 9 Rajagopal Postgrad Med J 2005

13 Intercurrent infection (Patho-)physiology Initial phase of infection Increased adherence of leucocytes to the vascular wall Leucocytes crossing the vascular wall Leucocyte migration towards the infected cell Death of leucocytes Result: lowered WBC plasma level = lowered WBC count Only later will infection result in increased production and levels of leucocytes (= leukocytosis)

14 Diurnal variation Diurnal variation: leucocytes counts in blood show diurnal variation lowest in the morning, highest in the afternoon Advise after the first leukopenia: - Rule out a mistake -> repeat WBC count from morning blood sample - Rule out diurnal variation -> WBC count from afternoon sample

15 Agranulocytosis Onset: 80-85% in the initial first 6 months Incidence Mortality Total population Affected cases 3, ,1 0,3 2,2%- 4,2% Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012

16 Treatment emergent agranulocytosis: general recommendation 1. Establish a working alliance with an internist and/or hematologist before initiation of clozapine treatment, whom you can consult if necessary. 2. When leukopenia emerges, consult the internist/hematologist.

17 1.a. Other uncommon serious side-effects - Diabetic Keto-Acidosis (DKA) - Myocarditis

18 Diabetic Keto-Acidosis Rarely occurring severe disruption of the glucose homeostasis or severe worsening of pre-existing DM Cause: acute shortage of insulin Pathophysiological mechanisms are unclear

19 Diabetic Keto-Acidosis Outcome: - metabolic acidosis - metabolic ketosis - if undetected and therefore untreated: coma and death

20 Diabetic Keto-Acidosis Reported cases occurred most frequently with olanzapine or clozapine But Cases have been reported with all atypical antipsychotics

21 Diabetic Keto-Acidosis in clozapine treatment Onset seems to be restricted to the initial 3 months of treatment Diagnosis may occur later, after the hyperglycemia has become more severe and has lead to metabolic complications. Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012

22 Diabetic Keto-Acidosis in clozapine treatment Incidence Mortality Total population Affected cases 1,2-3,1 0,2-4,4 20,0%- 31,0% Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012

23 Myocarditis Onset: restricted to the initial 1 month of treatment Incidence Mortality Total population Affected cases Australia 7, ,2 0%- 13% Rest of world 0,07 0,6 0-0,2 0%- 68%

24 b. Common & harmless: the case of constipation Constipation occurs in 25,1% of clozapine-treated patients. Danger: severe constipation can result in (sub-)ileus and eventually death. Meltzer InterSept Trial. Arch Gen Psychiatry 2003

25 Risk factors of GIH 1. Co-medication: anticholinergic drugs or other drugs that cause constipation. Caveat: medication is only co-medication from a psychiatric point of view, not from that of the GP or somatic specialist. 2. Dosage: more risk with higher dosage 3. Treatment duration: conflicting results. initial phase: 36% < 4 months, 50% < 1 year (Palmer) maintenance phase: mean duration 1528 days (Nielsen) Palmer J Clin Psych 2008; Nielssen & Meyer Schizophr Bull 2011

26 GIH: (sub-)ileus Incidence Mortality Total population Affected cases 4-8 0,98 1,19 15,0%- 27,5%

27 Comparison of incidence ( ) & mortality rates of all 4 dangerous side effects of clozapine. Incidence Mortality Total population ( ) Total population ( ) Incident cases Agranulocytosis 3,8 8,0 0,1-0,3 2,2-4,2% DKA 1,2-3,1 0,2-4,4 20,0-31,0% GIH 4,0-8,0 0,98-1,19 15,0-27,5 % Myocarditis: Australia 7,0 34,0 0-1,2 0-13% Rest of the world 0,07-0,6 0-0,2 0-68% Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012

28 Uncommon serious side-effects: agranulocytosis In general, psychiatrists are excessively worried over the chances and risks of agranulocytosis. They tend to be less worried about - some even unaware of other serious side effects. Both positions are wrong.

29 Incidence and mortality of agranulocytosis put into perspective Incidence Country Study pop Agranulocytosis Incidence USA N= cases 0.382% Australia N= cases 0.3% In the US-study, 12 patients died. Honigfeld J Clin Psych 1998; Drews Australasian Psych 2013

30 Incidence and mortality of agranulocytosis put into perspective Mortality rate - Affected population(12/382) = 3,14% - Total population (12/99.500) = 0,1 (= 1: patients) Honigfeld J Clin Psych 1998

31 Uncommon serious side-effects: incidence and mortality of agranulocytosis put into perspective Conclusion Within the framework of mandatory WBC monitoring, the risk of agranulocytosis is low and kept within acceptable borders.

32 Uncommon serious side-effects: agranulocytosis incidence and mortality in perspective Obligatory WBC-count has shown to be effective in preventing death as complications of agranulocytosis. What about the other 3 serious side-effects?

33 Screening advise for DKA, GIH and myocarditis Aim Reduction of the current high mortality rates to that of agranulocytosis

34 Screening advise DKA Baseline measurement of fasting plasma glucose (FPG) Monthly FPG measurement during the months at risk = the first 3 months of clozapine treatment Thereafter: yearly measurement of FPG

35 Screening advise DKA: the role of HbA1c HbA1c is a reliable predictor of long term DM complications reflects mean plasma glucose of the previous 2 months is therefore unsuitable for detection of rapidly developing new-onset DM and DKA

36 Screening advise GIH: two options and one obligation: Two options Option 1. Patients defecation pattern is a standard topic at every visit. Option 2. Patients defecation pattern is a standard topic at every visit and preventive prescription of macrocol laxative in all clozapine patients.

37 Screening advise GIH: two options and one obligation: Obligation Warn and inform the GP on - the risk of GIH as a side-effect of clozapine - the possibility of additional risk of constipation due to constipating effect of somatic (co-)medication.

38 Screening advise myocarditis 1. For reasons unknown, myocarditis in clozapine treatment is mainly a problem of Australia and New-Zealand. 2. There is no evidence that warrants routinely monitoring of treatment emergent myocarditis outside Australia and New- Zealand.

39 The special effect of clozapine: what is the right moment for prescription of this drug of last resort? Grant your patients a safe treatment with clozapine!

40 Thank you for your attention!

41 Questions?

Separating chaff from the wheat. Evidence-based obligatory screening of sideeffects in clozapine treatment.

Separating chaff from the wheat. Evidence-based obligatory screening of sideeffects in clozapine treatment. Separating chaff from the wheat. Evidence-based obligatory screening of sideeffects in clozapine treatment. Dan Cohen, psychiatrist FACT-team Heerhugowaard North-Holland North, Netherlands, Europe Disclosure

More information

Agranulocytosis in clozapine: myths and facts

Agranulocytosis in clozapine: myths and facts Agranulocytosis in clozapine: myths and facts Dr. P.F.J. Schulte, psychiatrist Mental Health Services Noord-Holland-Noord Alkmaar, Netherlands Statement of Potential Conflicts of Interest Agranulocytosis

More information

Ladies and gentlemen, good afternoon! Let me talk to you about myths and facts of clozapine. Of course you are all aware of the fact that clozapine

Ladies and gentlemen, good afternoon! Let me talk to you about myths and facts of clozapine. Of course you are all aware of the fact that clozapine Ladies and gentlemen, good afternoon! Let me talk to you about myths and facts of clozapine. Of course you are all aware of the fact that clozapine has unique efficacy in therapy refractory schizophrenia,

More information

STARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.

STARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management

More information

Clozapine, neutropenia and agranulocytosis, red alert management

Clozapine, neutropenia and agranulocytosis, red alert management Clozapine, neutropenia and agranulocytosis, red alert management The information in this document is not intended as a definitive treatment strategy, but as a suggested approach for clinicians. It is based

More information

First Steps: Considering Clozapine for your Patients

First Steps: Considering Clozapine for your Patients First Steps: Considering Clozapine for your Patients The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health

More information

For personal use only

For personal use only For mass reproduction, content licensing and permissions contact Dowden Health Media. Copyright Dowden Health Media For personal use only Clozapine, despite its side effect burden, may be the most effective

More information

Titrating Clozapine amidst Recommendations Proposing High Myocarditis Risk and Rapid Titrations

Titrating Clozapine amidst Recommendations Proposing High Myocarditis Risk and Rapid Titrations University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 10-2015 Titrating Clozapine amidst Recommendations Proposing High Myocarditis Risk and Rapid Titrations Jose de Leon University

More information

Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug

Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug Bahrain Medical Bulletin, Vol. 29, No.4, December 2007 Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug Mohammad Naeem Niazy, MRCP, FRCPI* Ghassan Baidas, MRCP, FRCPI* Thomas

More information

Dosing & Administration

Dosing & Administration Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an

More information

Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.

Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. 1 Benefits of Clozapine Clozapine may work when other medications don t. Doctors

More information

Datix Ref:

Datix Ref: Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document

More information

Clozapine and Polycythemia Rubra Vera: A Rare Side Effect or a Separate Medical Condition? A Case Report

Clozapine and Polycythemia Rubra Vera: A Rare Side Effect or a Separate Medical Condition? A Case Report CASE REPORT Clozapine and Polycythemia Rubra Vera: A Rare Side Effect or a Separate Medical Condition? A Case Report Tan HPJ Hospital Sentosa, Kuching, Sarawak, Malaysia Abstract This article highlights

More information

Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT

Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT Version: 1 Author: Ambreena Asghar Designation: Pharmacist Responsible Director: Sharon Binyon Approved By: Drugs and Therapeutics

More information

Pharmacotherapy of psychosis and schizophrenia in youth

Pharmacotherapy of psychosis and schizophrenia in youth Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,

More information

Should Psychiatrists be diagnosing (and treating) metabolic syndrome

Should Psychiatrists be diagnosing (and treating) metabolic syndrome Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file

More information

Clozapine is an atypical antipsychotic agent with

Clozapine is an atypical antipsychotic agent with CASE REPORT Continuing Clozapine Therapy Despite Morning Pseudoneutropenia Sean P Spina and Susan P Corrigan INTRODUCTION Clozapine is an atypical antipsychotic agent with demonstrated effectiveness for

More information

The licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia.

The licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia. 1. Introduction Future Directions CIC will support the use of the antipsychotic Clozapine in all appropriate cases. The purpose of this procedure is to set out the standards for Clinicians, Pharmacists,

More information

Dosing and administration information for ABILIFY MAINTENA (aripiprazole)

Dosing and administration information for ABILIFY MAINTENA (aripiprazole) DOSING AND ADMINISTRATION GUIDE Dosing and administration information for ABILIFY MAINTENA (aripiprazole) Approved for deltoid or gluteal administration ABILIFY MAINTENA (aripiprazole) is an atypical antipsychotic

More information

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Ref No: E050 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Please complete the following details: Patient s name,

More information

Clozapine Underutilization: Addressing the Barriers

Clozapine Underutilization: Addressing the Barriers Clozapine Underutilization: Addressing the Barriers Deanna L. Kelly, Pharm.D., BCPP Professor of Psychiatry Director, Treatment Research Program Maryland Psychiatric Research Center University of Maryland

More information

Integrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION

Integrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION Document Reference MM 048 Integrated Care Pathway (ICP) for the Management of clozapine INPATIENT INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant

More information

ESSENTIAL SHARED CAR E AGREEMENT FOR

ESSENTIAL SHARED CAR E AGREEMENT FOR E093 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in People with Learning Disability (LD) Referral Criteria In some

More information

Beyond clozapine: a review of the literature on clozapine resistance

Beyond clozapine: a review of the literature on clozapine resistance Beyond clozapine: a review of the literature on clozapine resistance Jan Bogers j.bogers@ggzleiden.nl www.clozapinepluswerkgroep.nl Dutch Clozapine Collaboration Group Mental Health Services Rivierduinen

More information

Shared Care Guideline for Olanzapine (Zyprexa )

Shared Care Guideline for Olanzapine (Zyprexa ) Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the

More information

Monitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH

Monitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH 1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives

More information

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare

More information

UNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Consultation-Liaison Psychiatry PaRK MHS, Western

UNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Consultation-Liaison Psychiatry PaRK MHS, Western UNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Consultation-Liaison Psychiatry PaRK MHS, Western Australia Talks Facilitator of the CTF Exam Prep Course

More information

ANTIPSYCHOTIC POLYPHARMACY

ANTIPSYCHOTIC POLYPHARMACY Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University

More information

Participating Hospital Certification Form

Participating Hospital Certification Form Participating Hospital Certification Form ATTENTION: this Certification Form is only applicable for Free Trial Product Units of ABILIFY MAINTENA (aripiprazole). Instructions: The Authorized Representative

More information

NCDPS Health Services Elissa Brody, CNM, BSN, RN Education Director June 2017

NCDPS Health Services Elissa Brody, CNM, BSN, RN Education Director June 2017 NCDPS Health Services Elissa Brody, CNM, BSN, RN Education Director June 2017 Disclosure NC Department of Public Safety Division of Adult Corrections/Prisons Health Services- Nursing Education NCNA Approved

More information

FDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extendedrelease injectable suspension in the Treatment of Schizophrenia

FDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extendedrelease injectable suspension in the Treatment of Schizophrenia FOR IMMEDIATE RELEASE FDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extendedrelease injectable suspension in the Treatment of Schizophrenia Patients being treated for schizophrenia

More information

ADMINISTRA TIVE/FISCAL/CLINICAUPHF POLICY AND PROCEDURES

ADMINISTRA TIVE/FISCAL/CLINICAUPHF POLICY AND PROCEDURES ADMINISTRA TIVE/FISCAL/CLINICAUPHF POLICY AND PROCEDURES COUNTY OF SANTA BARBARA ALCOHOL, DRUG AND MENTAL HEAL TH SERVICES Section - QUALITY ASSURANCE Effective: 12/1 /09 Policy- #56 CLOZAPINE PRESCRIBING

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

Psychopharmacological treatment of first episode psychosis

Psychopharmacological treatment of first episode psychosis Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center

More information

Physical Health Management: Why it s important for adolescents and young adults in mental health services

Physical Health Management: Why it s important for adolescents and young adults in mental health services Physical Health Management: Why it s important for adolescents and young adults in mental health services Early Intervention Service Wellington Lauren Heath and Erin Dawson Introduction Second generation

More information

LAIs and the Challenge of Medication Non-Adherence The Care Transitions Network

LAIs and the Challenge of Medication Non-Adherence The Care Transitions Network LAIs and the Challenge of Medication Non-Adherence The Care Transitions Network Lauren Hanna, M.D. The Zucker Hillside Hospital Northwell Health National Council for Behavioral Health Montefiore Medical

More information

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice

More information

More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications

More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Disclosure In the past 12 months I have received

More information

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance] SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm

More information

Role of Clozapine in Treatment-Resistant Schizophrenia

Role of Clozapine in Treatment-Resistant Schizophrenia Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant

More information

DIABETES MELLITUS. IAP UG Teaching slides

DIABETES MELLITUS. IAP UG Teaching slides DIABETES MELLITUS 1 DIABETES MELLITUS IN CHILDREN Introduction, Definition Classification, pathogenesis Clinical features Investigations and diagnosis Therapy and follow up Complications Carry home message

More information

Michael J. Bailey, M.D. OptumHealth Public Sector

Michael J. Bailey, M.D. OptumHealth Public Sector Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)

More information

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction

More information

Claire Thomas, Deputy Chief Pharmacist. Tim Donaldson, Trust Chief Pharmacist. Contents. Section Description Page No.

Claire Thomas, Deputy Chief Pharmacist. Tim Donaldson, Trust Chief Pharmacist. Contents. Section Description Page No. Pharmacological Therapy Policy Practice Guidance Note Safe Prescribing of Clozapine V02 Version issued Issue 1 Jan 16 Issue 2 Nov 16 Planned review January 2019 PPT-PGN-05 Part of NTW(C)38 Pharmacological

More information

CLOZAPINE. Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent.

CLOZAPINE. Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent. CLOZAPINE Introduction Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent. Due to its potential for significant toxicity, it is reserved for patients

More information

North Central London Medicines Optimisation Committee

North Central London Medicines Optimisation Committee North Central London Medicines Optimisation Committee Guidance for Pharmacy Staff Managing Clozapine For Patients Admitted to Acute Hospitals Disclaimer This guideline is registered at North Central London

More information

Dementia and Diabetes

Dementia and Diabetes Dementia and Diabetes Dr Jill Rasmussen RCGP Clinical Representative Dementia, jill.rasmussen@psi-napse.com 1 Dementia and Diabetes - Overview The Facts Implications for the Well Pathway Mild Cognitive

More information

Multicellular Organisms

Multicellular Organisms Multicellular Organisms Sub-Topic (2.2) Control and Communication Hormonal Control (b) On completion of this sub-topic I will be able to state that: Hormones are chemical messengers Hormones are released

More information

First Episode Schizophrenia

First Episode Schizophrenia First Episode Schizophrenia Abigail Donovan, M.D. Assistant Professor of Psychiatry, Harvard Medical School Director, First Episode and Early Psychosis Program MGH Schizophrenia Program Massachusetts General

More information

Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes

Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication

More information

BOXED WARNING 1. AGRANULOCYTOSIS BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE

BOXED WARNING 1. AGRANULOCYTOSIS BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE BOXED WARNING 1. AGRANULOCYTOSIS BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF SEVERELY ILL

More information

Diabetes Mellitus in the Pediatric Patient

Diabetes Mellitus in the Pediatric Patient Diabetes Mellitus in the Pediatric Patient William Bryant, M.D. Chief of Section Pediatric Endocrinology Children s Hospital at Scott & White Texas A&M University Temple, Texas Disclosures None Definitions

More information

Medication Audit Checklist- Antipsychotics - Atypical

Medication Audit Checklist- Antipsychotics - Atypical Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,

More information

DOSING AND ADMINISTRATION GUIDE

DOSING AND ADMINISTRATION GUIDE DOSING AND ADMINISTRATION GUIDE Indication TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient

More information

Integrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION

Integrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION Document Reference MM 049 Integrated Care Pathway (ICP) for the Management of clozapine COMMUNITY INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant

More information

Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD

Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine

More information

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used

More information

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate

More information

-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine

-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine -Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked

More information

Clozapine-induced concordant agranulocytosis

Clozapine-induced concordant agranulocytosis Ó 2001 Martin Dunitz Ltd International Journal of Psychiatry in Clinical Practice 2001 Volume 5 Pages 71 ± 73 71 Clozapine-induced concordant agranulocytosis in monozygotic twins J HORAÂ C Ï EK, J LIBIGER,

More information

Doubled risk of Depression in Diabetes Prevalence: 10-20%

Doubled risk of Depression in Diabetes Prevalence: 10-20% Bright Light Treatment for better Mood and Metabolic control: a Randomised Controlled Trial in patients with Type-2- Diabetes and Major Depressive Disorder Project group: Annelies Brouwer, PhD-student

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION CLOZAPINE TABLETS

HIGHLIGHTS OF PRESCRIBING INFORMATION CLOZAPINE TABLETS HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

Clinical Guideline for the Management of Bipolar Disorder in Adults

Clinical Guideline for the Management of Bipolar Disorder in Adults Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:

More information

VERSACLOZ (clozapine) oral suspension Initial U.S. Approval: 1989

VERSACLOZ (clozapine) oral suspension Initial U.S. Approval: 1989 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VERSACLOZ safely and effectively. See full prescribing information for VERSACLOZ. VERSACLOZ (clozapine)

More information

PRODUCT MONOGRAPH. CLOZARIL (Clozapine Tablets) 25 mg and 100 mg

PRODUCT MONOGRAPH. CLOZARIL (Clozapine Tablets) 25 mg and 100 mg PRODUCT MONOGRAPH Pr CLOZARIL (Clozapine Tablets) 25 mg and 100 mg Antipsychotic Agent HLS Therapeutics Inc. 10 Carlson Court, Suite 410 Etobicoke, Ontario M9W 6L2 Control No.: 205552 CLOZARIL is a registered

More information

Individualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD

Individualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases

More information

CLOZARIL (clozapine) tablets, for oral use. Initial U.S. Approval: 1989

CLOZARIL (clozapine) tablets, for oral use. Initial U.S. Approval: 1989 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CLOZARIL safely and effectively. See full prescribing information for CLOZARIL. CLOZARIL (clozapine)

More information

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:

More information

GENERAL PRACTITIONER (GP) SUPPORT PACK

GENERAL PRACTITIONER (GP) SUPPORT PACK Document Reference MM 050 Integrated Care Pathway (ICP) for the Management of clozapine GENERAL PRACTITIONER (GP) SUPPORT PACK One pack to be printed for each patient initiated on clozapine treatment,

More information

Pharmacological Managment of Treatment Resistant Schizophrenia. Jean-Marie Batail - France 21 st July 2015

Pharmacological Managment of Treatment Resistant Schizophrenia. Jean-Marie Batail - France 21 st July 2015 Pharmacological Managment of Treatment Resistant Schizophrenia Jean-Marie Batail - France 21 st July 2015 Introduction A chronic and debilitating illness - Lifetime prevalence of around 0,7%. - Beginning

More information

University of Groningen

University of Groningen University of Groningen A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole Schorr, S. G.; Slooff, C. J.; Postema, R.; Van Oven, W.; Schilthuis, M.; Bruggeman, Richard;

More information

5/12/2011. Recognize the major types of diabetes: Type 2, Type 1A, Type 1B, MODY, LADA, Pancreatic diabetes, drug-induced DM

5/12/2011. Recognize the major types of diabetes: Type 2, Type 1A, Type 1B, MODY, LADA, Pancreatic diabetes, drug-induced DM J. Christopher Lynch, Pharm.D. Professor Acting Associate Dean of Student Affairs Southern Illinois University Edwardsville School of Pharmacy The speaker has no conflicts of interest to disclose Recognize

More information

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines

More information

Clozapine Shared Care Protocol And Information For Oxfordshire GPs

Clozapine Shared Care Protocol And Information For Oxfordshire GPs Clozapine Shared Care Protocol And Information For Oxfordshire GPs There should be willing consent of all parties to enter into a shared care agreement. This includes patients (plus carers if necessary)

More information

PRODUCT MONOGRAPH. Clozapine Tablets. 25 mg, 50 mg, 100 mg and 200 mg. Pharmaceutical Standard: Mylan Std. Clozapine Oral Suspension.

PRODUCT MONOGRAPH. Clozapine Tablets. 25 mg, 50 mg, 100 mg and 200 mg. Pharmaceutical Standard: Mylan Std. Clozapine Oral Suspension. PRODUCT MONOGRAPH Pr GEN-CLOZAPINE Clozapine Tablets 25 mg, 50 mg, 100 mg and 200 mg Pharmaceutical Standard: Mylan Std. Clozapine Oral Suspension 50 mg/ml Antipsychotic Agent Mylan Pharmaceuticals ULC

More information

CLOZAPINE TREATMENT GUIDELINES MARCH 2017

CLOZAPINE TREATMENT GUIDELINES MARCH 2017 CLOZAPINE TREATMENT GUIDELINES MARCH 2017 0 Policy title Clozapine treatment guidelines Policy PHA06 reference Policy category All clinical staff who deal with medication in the Trust. Relevant to Clinical

More information

Clozapine associated diabetic acidosis

Clozapine associated diabetic acidosis www.edoriumjournals.com Letter To Editor open ACCESS Clozapine associated diabetic acidosis Kalliopi Kotsa, Evangelos Potolidis, Vasiliki Lygoura, Charalampos Mandros, Panagiotis Fanourgiakis ABSTRACT

More information

Urgent Medical Device Correction

Urgent Medical Device Correction Urgent Medical Device Correction Contact TM Detach Infusion Sets: Needle May Fracture From the Connect/Disconnect Location August 10, 2015 Dear Valued Customer: Unomedical a/s, a ConvaTec Company has initiated

More information

Now it s time for... Teva Clozapine. (Clozapine, USP Tablets and Orally Disintegrating Tablets) Patient & Family Guide to Teva Clozapine Therapy

Now it s time for... Teva Clozapine. (Clozapine, USP Tablets and Orally Disintegrating Tablets) Patient & Family Guide to Teva Clozapine Therapy Now it s time for... Teva Clozapine (Clozapine, USP Tablets and Orally Disintegrating Tablets) Patient & Family Guide to Teva Clozapine Therapy This is a very important time in your life You and your family

More information

Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID

Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID Although not considered first line treatment in children with ASD and ID, depending on the severity of symptoms, some medications

More information

Background. Population/Intervention(s)/Comparator/Outcome(s) (PICO) Duration of antipsychotic treatment in individuals with a first psychotic episode

Background. Population/Intervention(s)/Comparator/Outcome(s) (PICO) Duration of antipsychotic treatment in individuals with a first psychotic episode updated 2012 Duration of antipsychotic treatment in individuals with a first psychotic episode Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug

More information

Alameda County Behavioral Health Care Services

Alameda County Behavioral Health Care Services I. Background A. General Information Clozapine is an antipsychotic that is FDA approved for treatment-refractory schizophrenia and reduction of recurrent suicidal behavior in schizophrenia or schizoaffective

More information

Age / Sex: 31-year-old bi-racial male admitted to hospital through. Background:

Age / Sex: 31-year-old bi-racial male admitted to hospital through. Background: Stephen M. Goldfinger, MD Chart Review: The Patient You Hate to Treat PATIENT INFO 31 / Male Age / Sex: 31-year-old bi-racial male admitted to hospital through Background: Psychiatric Emergency Services.

More information

With Dr. Sarah Reid and Dr. Sarah Curtis

With Dr. Sarah Reid and Dr. Sarah Curtis 5. Headaches 6. Known diabetes 7. Specific high risk groups (ie. Teenagers, children on insulin pumps and those from lower socio-economic status). Episode 63 Pediatric Diabetic Ketoacidosis With Dr. Sarah

More information

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: 0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:

More information

You wrote ZYPREXA. Will your patient leave the pharmacy with something else? (cetirizine HCl) have been mistaken, one for the other, in the past.

You wrote ZYPREXA. Will your patient leave the pharmacy with something else? (cetirizine HCl) have been mistaken, one for the other, in the past. ZYPREXA (olanzapine)? You wrote ZYPREXA. Will your patient leave the pharmacy with something else? With over 4,000 drugs on the market and more than 8 million prescriptions filled every day, medication

More information

Aiming for recovery for patients with severe or persistent depression a view from secondary care. Chrisvan Koen

Aiming for recovery for patients with severe or persistent depression a view from secondary care. Chrisvan Koen Aiming for recovery for patients with severe or persistent depression a view from secondary care Chrisvan Koen Kent and Medway NHS and Social care Partnership trust Persistent depressive disorder F34 Persistent

More information

Diabetes distress 7 A s model

Diabetes distress 7 A s model Diabetes and emotional health: A toolkit for health s supporting adults with type 1 or type 2 diabetes Diabetes distress 7 A s model AWARE Be AWARE that people with diabetes may experience diabetes distress

More information

Integrating Behavioral Health into Primary Care: Collaborative-Care Models

Integrating Behavioral Health into Primary Care: Collaborative-Care Models Integrating Behavioral Health into Primary Care: Collaborative-Care Models Presented at the National Health Policy Forum September 17 th, 2013 Marc Avery, MD Clinical Associate Professor Associate Director

More information

Diabetes Mellitus and the Dental Healthcare Professional

Diabetes Mellitus and the Dental Healthcare Professional Diabetes Mellitus and the Dental Healthcare Professional Jerry A. Brown DMD, CDE University of South Florida Department of Internal Medicine jabrown7@health.usf.edu Learning Objectives Diabetes- The Disease

More information

Diabetes. Ref HSCW 024

Diabetes. Ref HSCW 024 Diabetes Ref HSCW 024 Why is it important? Diabetes is an increasingly common, life-long, progressive but largely preventable health condition affecting children and adults, causing a heavy burden on health

More information

Talking to Patients and Their Families

Talking to Patients and Their Families Talking to Patients and Their Families About Clozapine The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health

More information

CLOZAPINE. Generic? Yes

CLOZAPINE. Generic? Yes CLOZAPINE THERAPEUTICS Brands Clozaril Leponex Versacloz (oral suspension) Fazaclo ODT (oral disintegrating tablet) see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature:

More information

NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system

NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system The Freestyle Libre flash glucose monitoring system is a sensor based, factory-calibrated system that measures interstitial fluid

More information